Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Non-Current Liabilities: 2021-2023

Historic Total Non-Current Liabilities for Relay Therapeutics (RLAY) over the last 3 years, with Dec 2023 value amounting to $78.8 million.

  • Relay Therapeutics' Total Non-Current Liabilities fell 31.33% to $84.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $84.3 million, marking a year-over-year decrease of 31.33%. This contributed to the annual value of $78.8 million for FY2023, which is 32.77% down from last year.
  • Relay Therapeutics' Total Non-Current Liabilities amounted to $78.8 million in FY2023, which was down 32.77% from $117.2 million recorded in FY2022.
  • In the past 5 years, Relay Therapeutics' Total Non-Current Liabilities ranged from a high of $117.2 million in FY2022 and a low of $60.4 million during FY2021.
  • Over the past 3 years, Relay Therapeutics' median Total Non-Current Liabilities value was $78.8 million (recorded in 2023), while the average stood at $85.4 million.
  • In the last 5 years, Relay Therapeutics' Total Non-Current Liabilities surged by 94.07% in 2022 and then plummeted by 32.77% in 2023.
  • Relay Therapeutics' Total Non-Current Liabilities (Yearly) stood at $60.4 million in 2021, then skyrocketed by 94.07% to $117.2 million in 2022, then plummeted by 32.77% to $78.8 million in 2023.